Biotech Values

[dav1234]

DUSA Pharmaceuticals (DUSA) +37.7% premarket after agreeing to be acquired by India's Sun Pharma for $8/share, giving the deal a total cash value of ~$230M. The price represents a 38% premium to DUSA's closing price yesterday. Dermatology company DUSA develops and markets the Levulan photodynamic therapy platform for the face and scalp